PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
9.68M
Better than EYEN's estimated revenue of 3.80M.
-1.93M
Better than EYEN's estimated ebitda of -2.18M.
-1.38
Better than EYEN's estimated eps of -16.15.
-41.62M
Worse than EYEN's estimated net income of -13.45M.
-1.93M
Better than EYEN's estimated ebit of -2.19M.
358.54M
Better than EYEN's estimated sg&a expense of 2.69B.
Analyze DCF forecasts for the company and compare them with competitors.
1.14M
Worse than EYEN's revenue of 14.00M.
No Data
No DCF data available for this metric in the selected year.
-24.44M
Worse than EYEN's ebitda of -12.17M.
-2136.36%
Worse than EYEN's ebitda margin of -86.92%.
-24.96M
Worse than EYEN's ebit of -12.39M.
-2182.17%
Worse than EYEN's ebit margin of -88.50%.
524.00K
Worse than EYEN's depreciation of 221.56K.
77.83M
Better than EYEN's total cash of 19.46M.
6803.23%
Better than EYEN's cash as percentage of revenue of 139.01%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
5.54M
Worse than EYEN's accounts payable of 1.61M.
483.83%
Worse than EYEN's payables as percentage of revenue of 11.53%.
-133.00K
Worse than EYEN's capital expenditure of -1.62M.
-11.63%
Better than EYEN's capex as percentage of revenue of -11.56%.
4.99%
Better than EYEN's weighted average cost of capital (wacc) of 20.99%.
5.02%
Better than EYEN's cost of equity of 7.67%.
4.08%
Better than EYEN's cost of debt of 22.10%.
-0.23
Better than EYEN's beta of 0.76.
30.07M
Worse than EYEN's diluted shares outstanding of 833.00K.
1.57M
Better than EYEN's total debt of 11.24M.
49.31M
Better than EYEN's total equity of 941.29K.
50.89M
Better than EYEN's total capital of 12.18M.
3.09%
Better than EYEN's debt weighting of 92.27%.
96.91%
Better than EYEN's equity weighting of 7.73%.
-24.77M
Worse than EYEN's ebiat of -12.60M.
-23.19M
Worse than EYEN's unlevered free cash flow of -11.27M.
2.00%
Equal to EYEN's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Better than EYEN's net debt of 9.12M.
71.33M
Better than EYEN's equity value of -11.30M.
2.37
Better than EYEN's equity value per share of -13.56.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.